SCIENTIFIC LITERATURE · MED

The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.

Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, PKDS009 Study Group.

CNS Drugs · 2004-01-01

DOI: 10.2165/00023210-200418110-00003PMID: 15330687

Check source for accessComparative Study; Clinical Trial; Research Support, Non-U.S. Gov't; Multicenter Study; Randomized Controlled Trial; Journal ArticleOriginal source ↗

Research overview

Source publication and reading guides

This section identifies the original publication. Follow the source for its authors and journal.

Read the original publication ↗

Scientific assessment

Research question

Assess the question within the original study’s scope.

Methods & sample

Check the source article for study design and sample details.

Key findings

An editorially approved findings summary is not yet published for this record.

Limitations

Generalizability, bias and clinical meaning require separate assessment.

Methods, samples and clinical conclusions are not inferred from bibliographic metadata.